Business Wire

Trump International Hotel Washington, D.C. Announced as First Forbes Five Star Hotel in Downtown Washington, D.C.

Del

Trump International Hotel Washington, D.C. announces today that it has been awarded the 2018 Forbes Five-Star recognition, making it the first hotel to receive the prestigious distinction in Downtown Washington D.C. Forbes Travel Guide, the global authority on luxury travel, sends anonymous professional inspectors around the world to assess hotels, restaurants and spas against up to 800 objective standards focused on service and facilities. Just opened a short fifteen months ago, the property is located on Pennsylvania Avenue in the center of the city at the site of the Old Post Office.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222006277/en/

Trump International Hotel Washington, D.C. (Photo: Business Wire)

Trump International Hotel Washington, D.C. (Photo: Business Wire)

Mickael Damelincourt, Managing Director, oversaw the recruitment and selection of the executives whose teams would lead the hotel through the construction and opening phases, instilling a commitment to the highest levels of service excellence and dedication to the guests along the way.

“From when I first saw the Old Post Office in 2014, I imagined a luxury hotel that would compete with the finest hotels in other world capitals, as I listened to the vision of The Trump Organization,” said Damelincourt. “It has the three necessary components of an outstanding hotel: central location, iconic and memorable design and, most importantly, the anticipatory service and cultural awareness expected by our guests. It is now officially recognized as Washington’s best downtown hotel.”

Since 1958, the coveted Five Star Award rating from Forbes has been an honor bestowed on fewer than 200 properties worldwide meeting the hotel industry's most stringent hospitality benchmarks of over 800 service points. Achieving this distinction in the first year of operation is a rarity and a testimony to Damelincourt’s leadership and vision for the property.

“It is good news when a Washington, D.C. hotel is recognized for the superior level of service and product which they offer, and we’re proud that the Trump Hotel has been added as the city’s second property to the prestigious Forbes Five Star list. It’s an incredible recognition in such a short period of time and well deserved,” said Elliott L. Ferguson, II, president and CEO of Destination DC, the official destination marketing organization for the nation’s capital.

To celebrate receiving the Forbes Five-Star accolade for its numerous properties, Trump Hotels will offer a special limited time promotion offering guests to book two nights and save 50% off the third night. The promotion will be valid for all hotels and is available for booking from February 20 to March 31.

“While Trump D.C. is unquestionably among the most iconic and spectacular properties in the world, it is our incredible hotel team and the unparalleled service they deliver that has made this recognition possible,” said Trump Organization Executive Vice President Eric Trump.

Trump International Hotel Washington, D.C. joins four sister properties within the Trump Hotels brand portfolio which were also recognized as Forbes Five-Star hotels: Trump International Hotel & Tower® Vancouver; Trump International Hotel & Tower® New York; Trump International Hotel & Tower® Chicago; and Trump® International Hotel Waikiki.

Forbes Travel Guide is the gold standard for luxury hospitality ratings worldwide. For more information about Forbes Travel Guide, visit ForbesTravelGuide.com. For a detailed explanation of how Forbes Travel Guide compiles its Star ratings, click here.

Trump International Hotel Washington, D.C.

The recently opened Trump International Hotel, Washington, D.C. features 263 richly luxurious guest rooms and suites, among the largest in Washington, D.C., with lofty 16-foot ceilings, soaring windows, beautifully restored historic millwork, and glittering crystal sconces and chandeliers. The thirty-five suites include the Trump Townhouse with its private entrance on Pennsylvania Avenue. At 6,300 square feet of interior space, it is the largest and most luxurious suite in Washington, D.C. and among the largest in the country. The hotel also offers a total of 38,000 square feet of meeting and event space, including the opulent 13,200-square-foot Presidential Ballroom, the largest among D.C. luxury hotels, a 10,000-square-foot Spa by IVANKA TRUMP™ and Fitness Center, and D.C.’s first BLT Prime restaurant by Chef David Burke.

About TRUMP HOTEL GROUP™

Trump® Hotel Group is the world-renowned hotel brand and management company home to Trump Hotels™, SCION™ Hotels and Resorts and American IDEA™ Hotels. Led by seasoned hotel industry veteran Eric Danziger, Trump Hotel Group is part of The Trump Organization, helmed by Donald Trump Jr. and Eric Trump.

Contact information

Trump Hotel Group
Patricia Tang, 202-868-5010
Director, Sales & Marketing
ptang@trumphotels.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 07:06Pressemelding

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an

STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 07:00Pressemelding

Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 02:53Pressemelding

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 14:59Pressemelding

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch